Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MIRM Mirum Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: MIRM
Price (delayed)
$44.27
Market cap
$2.19B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
$2.3B
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat,
Highlights
The company's gross profit has surged by 78% YoY and by 15% QoQ
The revenue has soared by 69% YoY and by 13% from the previous quarter
The quick ratio has declined by 13% year-on-year but it is up by 3.2% since the previous quarter
The company's debt rose by 2.6% YoY
Key stats
What are the main financial stats of MIRM
Market
Valuations
Earnings
Shares outstanding
49.53M
Market cap
$2.19B
Enterprise value
$2.3B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.3
Price to sales (P/S)
5.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.05
Revenue
$379.25M
Gross profit
$292.42M
Operating income
-$76.32M
Net income
-$77.34M
EBIT
-$61.58M
EBITDA
-$35.81M
Free cash flow
-$7.87M
Per share
Balance sheet
Liquidity
EPS
-$1.61
EPS diluted
-$1.61
Free cash flow per share
-$0.16
Book value per share
$4.76
Revenue per share
$7.76
TBVPS
$9.13
Total assets
$690.25M
Total liabilities
$456.99M
Debt
$315.51M
Equity
$233.26M
Working capital
$283.24M
Debt to equity
1.35
Current ratio
3.22
Quick ratio
2.93
Net debt/EBITDA
-2.88
Margins
Efficiency
Dividend
EBITDA margin
-9.4%
Gross margin
77.1%
Net margin
-20.4%
Operating margin
-20.1%
Return on assets
-11.5%
Return on equity
-33.6%
Return on invested capital
-15.7%
Return on capital employed
-10.9%
Return on sales
-16.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIRM stock price
How has the Mirum Pharmaceuticals stock price performed over time
Intraday
-2.14%
1 week
1.33%
1 month
6.75%
1 year
71.39%
YTD
7.06%
QTD
-1.73%
Financial performance
How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$379.25M
Gross profit
$292.42M
Operating income
-$76.32M
Net income
-$77.34M
Gross margin
77.1%
Net margin
-20.4%
The company's gross profit has surged by 78% YoY and by 15% QoQ
The company's net margin has surged by 71% YoY and by 22% QoQ
The revenue has soared by 69% YoY and by 13% from the previous quarter
The operating margin has soared by 58% YoY and by 23% from the previous quarter
Price vs fundamentals
How does MIRM's price correlate with its fundamentals
Growth
What is Mirum Pharmaceuticals's growth rate over time
Valuation
What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.3
P/S
5.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.05
The EPS has soared by 57% YoY and by 13% from the previous quarter
MIRM's price to book (P/B) is 50% higher than its 5-year quarterly average of 6.2 and 12% higher than its last 4 quarters average of 8.3
Mirum Pharmaceuticals's equity has increased by 3.4% from the previous quarter
The revenue has soared by 69% YoY and by 13% from the previous quarter
MIRM's price to sales (P/S) is 61% lower than its 5-year quarterly average of 14.6 and 4.8% lower than its last 4 quarters average of 6.0
Efficiency
How efficient is Mirum Pharmaceuticals business performance
The ROS has soared by 75% YoY and by 25% from the previous quarter
The ROIC has soared by 65% YoY and by 22% from the previous quarter
Mirum Pharmaceuticals's return on assets has surged by 57% YoY and by 14% QoQ
The ROE has soared by 56% YoY and by 12% QoQ
Dividends
What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIRM.
Financial health
How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 51% higher than its total liabilities
The company's current ratio fell by 13% YoY but it rose by 3.9% QoQ
The quick ratio has declined by 13% year-on-year but it is up by 3.2% since the previous quarter
The company's debt is 35% higher than its equity
The debt to equity has contracted by 3.6% from the previous quarter but it has grown by 3.1% YoY
Mirum Pharmaceuticals's equity has increased by 3.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.